DREAMM-14

About this trial

The target population for this study are patients with relapsed refractory multiple myeloma

Patient Profile

The target population for this study are patients with relapsed refractory multiple myeloma

Where’s this trial being run?

Beaumont Hospital, Cork University Hospital, St James’s Hospital, and University Hospital Limerick

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.


Summary Data

Name: DREAMM-14
Number: 21-47
Full Title:

A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participants with Relapsed or Refractory Multiple Myeloma (DREAMM-14)

Principal Investigator: Dr John Quinn
Type: Industry Sponsored
Sponsor:

GSK

Recruitment Started: Global: 03 March 2022
Ireland: 21 August 2022
Global Recruitment Target: 180
Ireland Recruitment Target: 10